================================================================================
CLINICAL TRIALS MATCHING REPORT
================================================================================

Patient ID: 2
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G3 NET, Ki67 48%.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
Clinical Question: Weitere Therapie?
Report generated: 2025-07-10 11:19:29

Found 15 relevant clinical trials
--------------------------------------------------------------------------------

1. 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
   NCT ID: NCT06395402
   Status: RECRUITING
   Phase: PHASE2
   Relevance Score: 0.900
   Relevance Reason: Die Studie ist für diesen Patienten hochrelevant. Der Patient leidet an einem neuroendokrinen Tumor (NET) des Dünndarms mit Lymphknoten- und Lebermetastasen, was exakt der Indikation für die Behandlung mit Lutetium-177-DOTATATE (Lutathera) entspricht, die in der Studie untersucht wird. Der Tumor des Patienten ist ein G3 NET mit einem hohen Ki67-Wert von 48%, was auf eine höhere Aggressivität und potenziell eine höhere Sensitivität für die Therapie mit Lutetium-177 hinweist.
   Condition: Neuroendocrine Tumors; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2
   Intervention: Lutetium Lu 177 dotatate therapy
   Sponsor: University of Iowa
   Start Date: 2024-05-03
   Completion Date: 2029-12-31
   Locations: Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, United States
   URL: https://clinicaltrials.gov/study/NCT06395402
   Summary: The goal of this study is to learn if individualized dosimetry-based prescribing of Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals) improves treatment outcomes for adults with unresectable neuroendocrine tumors. To investigate this, study participants will:

* Undergo Somatostatin Recept...
----------------------------------------

2. Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients
   NCT ID: NCT04917484
   Status: RECRUITING
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie "Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients" ist für diesen Patienten hochrelevant. Hier ist die detaillierte Begründung:
   Condition: Neuroendocrine Neoplasm
   Intervention: Lu-177-DOTA-Octreotide
   Sponsor: Tine Gregersen, MD
   Start Date: 2020-02-01
   Completion Date: 2026-12
   Locations: Aarhus University Hospital, department of Nuclear medicine and PET centre, Aarhus, Denmark
   URL: https://clinicaltrials.gov/study/NCT04917484
   Summary: In this study, we want to randomize patients with neuroendocrine neoplasms (NENs) who are eligible for peptide receptor radionuclide therapy (PRRT), to either standard PRRT consisting of 4 treatments with 7.4 GBq Lu-177-DOTATOC (standard arm) or 4 treatments with individualized doses of Lu-177-DOTAT...
----------------------------------------

3. Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
   NCT ID: NCT03420521
   Status: TERMINATED
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie scheint für den Patienten hochrelevant zu sein. Hier ist die detaillierte Begründung:
   Condition: Neuroendocrine Tumors; Carcinoid Tumor
   Intervention: Nivolumab; Ipilimumab
   Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
   Start Date: 2018-03-09
   Completion Date: 2021-11-24
   Locations: Johns Hopkins Medical Institution, Baltimore, United States
   URL: https://clinicaltrials.gov/study/NCT03420521
   Summary: This is a single arm open-label design study looking at Nivolumab plus Ipilimumab in patients with Advanced Neuroendocrine Tumors. Patients will be dosed Nivolumab 240mg IV over 60 minutes every 2 weeks (Q2W) and Ipilimumab 1mg/kg IV over 30 minutes every 6 weeks (Q6W). One cycle will include 3 dose...
----------------------------------------

4. Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
   NCT ID: NCT03043664
   Status: COMPLETED
   Phase: PHASE1
   Relevance Score: 0.800
   Relevance Reason: Die Studie "Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors" ist für diesen Patienten hochrelevant.
   Condition: Gastroenteropancreatic Neuroendocrine Tumors
   Intervention: Lanreotide; Pembrolizumab
   Sponsor: Duke University
   Start Date: 2017-07-01
   Completion Date: 2022-06-07
   Locations: Duke University Medical Center, Durham, United States; Lexington Medical Center, Columbia, United States
   URL: https://clinicaltrials.gov/study/NCT03043664
   Summary: This study is for patients with non-resectable, recurrent, or metastatic well or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The study will be conducted in two stages: 1) Safety Run-In and 2) Expanded Cohort.

1. Safety run-in: The first stage will include a s...
----------------------------------------

5. Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
   NCT ID: NCT02859064
   Status: TERMINATED
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für den Patienten sehr relevant.
   Condition: Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoid Tumors
   Intervention: Lanreotide; Y-90 microspheres
   Sponsor: SCRI Development Innovations, LLC
   Start Date: 2017-07-28
   Completion Date: 2022-06-10
   Locations: Rocky Mountain Cancer Center, Denver, United States; Research Medical Center/HCA Midwest, Kansas City, United States; Tennessee Oncology PLLC, Nashville, United States
   URL: https://clinicaltrials.gov/study/NCT02859064
   Summary: Neuroendocrine tumors (NETs) and cancers that originate from the gastrointestinal tract can be resistant to standard chemotherapy and often metastasize to the liver. Lanreotide (Somatuline® Depot) Injection and Yttrium-90 microspheres (SIR-Spheres®) each have FDA approval to treat patients with meta...
----------------------------------------

6. Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
   NCT ID: NCT01678664
   Status: COMPLETED
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie "Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors" ist für diesen Patienten hochrelevant.
   Condition: Neuroendocrine Tumors; Hepatic Metastases; Metastases
   Intervention: Everolimus; embolization; Doxorubicin
   Sponsor: Federation Francophone de Cancerologie Digestive
   Start Date: 2012-12
   Completion Date: 2019-04
   Locations: CHU - Hôtel Dieu, Angers, France; Hôpital Avicenne, Bobigny, France; Hôpital Saint André, Bordeaux, France
   URL: https://clinicaltrials.gov/study/NCT01678664
   Summary: Determine wether 24 months treatment with everolimus prolongs progression free survival rate (based on a central assessment) after embolisation ou chemoembolisation for liver metastases.

* H0 a 24 months progression free survival rate less than 35% is unacceptable
* H1 a 24 months progression free ...
----------------------------------------

7. Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
   NCT ID: NCT05746208
   Status: RECRUITING
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie scheint für den Patienten sehr relevant zu sein. Hier ist eine detaillierte Begründung:
   Condition: Neuroendocrine Tumors; Well-Differentiated Neuroendocrine Carcinoma; High Grade Neuroendocrine Carcinoma, Any Site
   Intervention: Lenvatinib; Pembrolizumab; Hyperpolarized 13C-Pyruvate
   Sponsor: University of California, San Francisco
   Start Date: 2023-07-17
   Completion Date: 2027-10-31
   Locations: University of California, San Francisco, San Francisco, United States
   URL: https://clinicaltrials.gov/study/NCT05746208
   Summary: This is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET). First described in the pancreas in 2017, the classification was broadened to include gastrointestinal tract tumors in 2019. Recent data sugge...
----------------------------------------

8. Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
   NCT ID: NCT05724108
   Status: RECRUITING
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für den Patienten sehr relevant. Der Patient leidet an einem metastasierten neuroendokrinen Tumor (NET) des Dünndarms mit Lymphknoten- und Lebermetastasen, was direkt der Studienindikation entspricht ("Metastatic Neuroendocrine Tumors"). Der Patient wurde bereits operiert (Hemicolektomie und Ileumresektion), was typisch für das Krankheitsstadium ist, bevor eine systemische Therapie in Betracht gezogen wird. Die Fragestellung "Weitere Therapie?" passt perfekt zum Studienziel, die Wirksamkeit einer zusätzlichen Therapie (Triapine) zu untersuchen.
   Condition: Metastatic Neuroendocrine Tumor
   Intervention: Biospecimen Collection; Computed Tomography; Lutetium Lu 177 Dotatate; Magnetic Resonance Imaging; Triapine
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2023-08-30
   Completion Date: 2025-09-30
   Locations: City of Hope Comprehensive Cancer Center, Duarte, United States; UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, United States; UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, United States
   URL: https://clinicaltrials.gov/study/NCT05724108
   Summary: This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other pl...
----------------------------------------

9. Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
   NCT ID: NCT05359146
   Status: RECRUITING
   Phase: EARLY_PHASE1
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für den Patienten sehr relevant. Der Patient leidet an einem Dünndarm-NET mit Lebermetastasen, was direkt in den Fokus der in der Studie genannten gastroenteropankreatischen neuroendokrinen Tumoren (GEP-NETs) fällt. Die Studie untersucht eine neue Form der PRRT mit 161Tb-DOTA-LM3, die potenziell effektiver sein könnte als die Standardbehandlung mit 177Lu-DOTATOC/DOTATATE.
   Condition: Neuroendocrine Neoplasia's (NENs); Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
   Intervention: 161Tb-DOTA-LM3; 177Lu-DOTATOC
   Sponsor: University Hospital, Basel, Switzerland
   Start Date: 2023-03-28
   Completion Date: 2025-12
   Locations: Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
   URL: https://clinicaltrials.gov/study/NCT05359146
   Summary: The goal of this phase 0 proof-of concept study is to measure the therapeutic index (tumour to dose-limiting-organ dose ratios) of 161Tb-DOTA-LM3 in comparison to the current standard 177Lu-DOTATOC in the same gastroenteropancreatic neuroendocrine tumour (GEP-NET) patients in a randomized, cross-ove...
----------------------------------------

10. Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
   NCT ID: NCT05987176
   Status: RECRUITING
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für diesen Patienten hochrelevant. Der Patient leidet an einem neuroendokrinen Tumor (NET) des Dünndarms mit Lebermetastasen, was exakt der Patientenpopulation entspricht, die in der Studie untersucht wird. Die Studie vergleicht eine adjuvante Therapie mit 177Lu-DOTATATE nach Resektion von Lebermetastasen mit der besten unterstützenden Behandlung. Der Patient hat bereits eine Resektion des Primärtumors und der Lebermetastasen erfahren (Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie), was ihn für die Teilnahme an der Studie qualifiziert, da die Randomisierung kurz nach der Leberoperation erfolgen soll.
   Condition: Neuroendocrine Tumor G1 (NET G1)/Carcinoid; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumors; Liver Metastases; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Neoplasm
   Intervention: Lutathera
   Sponsor: Imperial College London
   Start Date: 2024-08-02
   Completion Date: 2029-03-30
   Locations: Imperial College Healthcare NHS Trust, London, United Kingdom
   URL: https://clinicaltrials.gov/study/NCT05987176
   Summary: An international multi-centre, open, randomised, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE to best supportive care in patients after complete surgical removal of neuroendocrine liver metastases.

In this study, adjuvant treatment with 177Lu-DOTATATE will be compa...
----------------------------------------

11. 68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
   NCT ID: NCT05673031
   Status: RECRUITING
   Phase: N/A
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für diesen Patienten hochrelevant. Der Patient leidet an einem neuroendokrinen Tumor (NET) des Dünndarms mit Metastasen in Lymphknoten und Leber, was direkt der Zielgruppe der Studie entspricht. Die Studie untersucht die Nützlichkeit von 68Ga-HA-DOTATATE PET/CT bei NETs, sowohl in der Primärdiagnostik als auch in der Surveillance nach Resektion.
   Condition: Neuroendocrine Tumors (NET)
   Intervention: 68Ga-HA-DOTATATE PET/CT imaging
   Sponsor: Alberta Health services
   Start Date: 2023-02-01
   Completion Date: 2027-01-01
   Locations: Foothills Medical Center 1403 29 St NW, Calgary, Canada
   URL: https://clinicaltrials.gov/study/NCT05673031
   Summary: To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available\]
----------------------------------------

12. 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
   NCT ID: NCT05448157
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für diesen Patienten sehr relevant. Der Patient hat ein Dünndarm-NET mit Lymphknoten- und Lebermetastasen (G3, Ki67 48%), was direkt in die Studienindikation von gastro-entero-pancreatic neuroendokrinen Tumoren (GEP-NETs) fällt. Insbesondere wird in der Studie explizit auf kleine Darm-NETs (SI-NETs) eingegangen, was für diesen Fall besonders wichtig ist.
   Condition: Neuroendocrine Tumor Carcinoid; Neuroendocrine Tumor of Pancreas; Gep Net
   Intervention: 
   Sponsor: European Institute of Oncology
   Start Date: 2022-05-12
   Completion Date: 2023-12-12
   Locations: IRCCS Istituto Europeo di Oncologia S.r.l., Milan, Italy
   URL: https://clinicaltrials.gov/study/NCT05448157
   Summary: In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates. In GEP-NETs the actual surgical planning is established on the ground of preoperative morphology images (CT scan), and functional imaging using CT/PET with 68Ga-DOT...
----------------------------------------

13. Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
   NCT ID: NCT01524783
   Status: COMPLETED
   Phase: PHASE3
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für diesen Patienten hochrelevant.
   Condition: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
   Intervention: Everolimus; Placebo; Best suportive care (BSC)
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2012-03-30
   Completion Date: 2020-08-07
   Locations: University of California San Diego - Moores Cancer Center Regulatory, La Jolla, United States; Scripps Clinic Regulatory, La Jolla, United States; Cedars Sinai Medical Center SC, Los Angeles, United States
   URL: https://clinicaltrials.gov/study/NCT01524783
   Summary: The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of, or current symptoms of c...
----------------------------------------

14. A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
   NCT ID: NCT04946305
   Status: COMPLETED
   Phase: N/A
   Relevance Score: 0.800
   Relevance Reason: Die Studie untersucht Lutathera® bei somatostatinrezeptor-positiven gastroenteropankreatischen neuroendokrinen Tumoren (GEP-NET). Der Patient hat einen NET des Dünndarms (Ileum) mit Lebermetastasen, was eindeutig unter die GEP-NET-Kategorie fällt. Der hohe Ki67-Wert von 48% deutet auf ein aggressiveres Tumorwachstum hin, was die Notwendigkeit einer systemischen Therapie verstärkt. Lutathera® ist eine Therapieoption, die bei fortgeschrittenen, gut differenzierten GEP-NETs eingesetzt wird, die somatostatinrezeptor-positiv sind.
   Condition: Somatostatin Receptor-positive GEP-NET
   Intervention: Lutathera
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2022-05-10
   Completion Date: 2024-07-08
   Locations: Novartis Investigative Site, Seongnam Si, Korea, Republic of; Novartis Investigative Site, Seoul, Korea, Republic of; Novartis Investigative Site, Seoul, Korea, Republic of
   URL: https://clinicaltrials.gov/study/NCT04946305
   Summary: This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.
----------------------------------------

15. A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
   NCT ID: NCT01262235
   Status: COMPLETED
   Phase: PHASE1
   Relevance Score: 0.800
   Relevance Reason: Die Studie "A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients" ist für diesen Patienten hochrelevant.
   Condition: Cancer; Neuroendocrine Tumors; NET; Adrenocortical Carcinoma; ACC
   Intervention: TKM-080301
   Sponsor: Arbutus Biopharma Corporation
   Start Date: 2010-12
   Completion Date: 2015-08
   Locations: Scottsdale Healthcare Research Institute, Scottsdale, United States; Mayo Clinic Arizona, Scottsdale, United States; Moffitt Cancer Center, Tampa, United States
   URL: https://clinicaltrials.gov/study/NCT01262235
   Summary: This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid tumors or lymphomas that are refractory to standard therapy or for who...
----------------------------------------